Abstract
In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.
Cite
CITATION STYLE
APA
Chandio, I. A., & Matori, A. N. B. (2011). GIS-based Multi-criteria Decision Analysis of Land Suitability for Hillside Development. International Journal of Environmental Science and Development, 469–473. https://doi.org/10.7763/ijesd.2011.v2.171
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free